Literature DB >> 1923504

Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene.

G Casey1, M Lo-Hsueh, M E Lopez, B Vogelstein, E J Stanbridge.   

Abstract

Mutations in the p53 gene are associated with a wide variety of human tumors, including those of the breast. To assess functionally the role of the p53 gene in the development of human breast cancer, we introduced either wild-type or mutant p53 cDNA into three human breast cancer cell lines by DNA transfection. The cell lines MDA-MB 468 and T47 D contain only single mutated copies of the p53 gene, whereas the status of p53 in the breast cancer cell line MCF 7 remains equivocal. Following transfection, MCF 7 cells continued to grow unaffected both in vitro and in vivo in the presence of high levels of expression of the exogenous wild-type p53 gene. In contrast, however, the continued expression of an exogenous wild-type p53 gene was incompatible with cellular growth in both the MDA-MB 468 and T47 D cell lines. Elevated levels of expression of the exogenous mutant p53 gene did not alter the growth of the cell lines in vitro. These data strongly suggest that the wild-type p53 gene can function as a suppressor of cellular growth in breast cancer cells. That the wild-type p53 gene does not suppress the growth of MCF 7 cells indicates that at least some human breast tumors can arise without functional inactivation of the p53 gene by mutation. These tumors may represent a separate prognostic group.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1923504

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  42 in total

Review 1.  Cancer risks from germline p53 mutations.

Authors:  T Frebourg; S H Friend
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

2.  Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome.

Authors:  A Reles; A Schmider; M F Press; I Schönborn; W Friedmann; S Huber-Schumacher; T Strohmeyer; W Lichtenegger
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

3.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

4.  Tumorigenicity of MCF-7 human breast cancer cells lacking the p38α mitogen-activated protein kinase.

Authors:  Rhone A Mendoza; Emily E Moody; Marlene I Enriquez; Sylvia M Mejia; Gudmundur Thordarson
Journal:  J Endocrinol       Date:  2010-10-25       Impact factor: 4.286

5.  p53 mediates senescence-like arrest induced by chronic replicational stress.

Authors:  Andriy Marusyk; Linda J Wheeler; Christopher K Mathews; James DeGregori
Journal:  Mol Cell Biol       Date:  2007-05-21       Impact factor: 4.272

6.  RGS-GAIP-interacting protein controls breast cancer progression.

Authors:  Ling Wang; Julie S Lau; Chitta Ranjan Patra; Ying Cao; Santanu Bhattacharya; Shamit Dutta; Debashis Nandy; Enfeng Wang; Chamila N Rupasinghe; Pawan Vohra; Mark R Spaller; Debabrata Mukhopadhyay
Journal:  Mol Cancer Res       Date:  2010-10-27       Impact factor: 5.852

7.  Mammary tumors initiated by constitutive Cdk2 activation contain an invasive basal-like component.

Authors:  Patrick E Corsino; Bradley J Davis; Peter H Nørgaard; Nicole N Teoh Parker; Mary Law; William Dunn; Brian K Law
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice.

Authors:  G Li; D L Mitchell; V C Ho; J C Reed; V A Tron
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

9.  Radiation resistance in breast cancer: are CD44+/CD24-/proteosome low/PKH26+ cells to blame?

Authors:  Harikrishna Nakshatri
Journal:  Breast Cancer Res       Date:  2010-04-07       Impact factor: 6.466

10.  Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro.

Authors:  Nik Soriani Yaacob; Nurraihana Hamzah; Nik Nursyazni Nik Mohamed Kamal; Siti Amalina Zainal Abidin; Choon Sheen Lai; Visweswaran Navaratnam; Mohd Nor Norazmi
Journal:  BMC Complement Altern Med       Date:  2010-08-05       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.